We have learned that RhoA is an upstream regulator of SRF-MRTFA, a potential therapeutic target for malignant tumors [26], and further activates the expression of G-actin, F-actin, and other transcription factors in cancer cells [34]. The gene discussed is SRF; the disease is cancer.